CG ONCOLOGY
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
CG ONCOLOGY
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2010-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.cgoncology.com
Total Employee:
11+
Status:
Active
Contact:
949-200-7680
Email Addresses:
[email protected]
Total Funding:
92.57 M USD
Technology used in webpage:
Google Apps For Business Google Maps Google Maps API Namecheap DNS
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Audeo Oncology Inc
Audeo Oncology is a biopharmaceutical company utilizing hyaluronic acid chemotransport technology.
Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer.
Cellular Biomedicine Group
CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Prothena
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
Current Employees Featured
Founder
Investors List
ORI Capital
ORI Capital investment in Series D - CG Oncology
Camford Capital
Camford Capital investment in Series D - CG Oncology
Kissei Pharmaceutical
Kissei Pharmaceutical investment in Series D - CG Oncology
Perseverance Capital Management
Perseverance Capital Management investment in Series D - CG Oncology
ORI Capital
ORI Capital investment in Series C - CG Oncology
Perseverance Capital Management
Perseverance Capital Management investment in Series C - CG Oncology
Whitesun Healthcare Ventures
Whitesun Healthcare Ventures investment in Series B - CG Oncology
Ally Bridge Group
Ally Bridge Group investment in Series B - CG Oncology
Song Hong Fang
Song Hong Fang investment in Series B - CG Oncology
WI Harper Group
WI Harper Group investment in Series B - CG Oncology
Official Site Inspections
http://www.cgoncology.com
- Host name: 69.19.212.35.bc.googleusercontent.com
- IP address: 35.212.19.69
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "CG Oncology"
About - CG Oncology
In addition to leading our business development, corporate strategy, quality, regulatory affairs, and supply chain organization. Ambaw has over 30 years of experience in the biotech …See details»
CG Oncology, Inc. (CGON) Company Profile & Facts - Yahoo Finance
See the company profile for CG Oncology, Inc. (CGON) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
CG Oncology - Crunchbase Company Profile & Funding
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies.See details»
CG Oncology - LinkedIn
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients ...See details»
Investor Relations | CG Oncology
Oct 31, 2024 CG ONCOLOGY, INC. 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618See details»
CG Oncology, Inc. (CGON) Company Profile & Overview - Stock …
Jan 25, 2024 400 Spectrum Center Drive, Suite 2040 Irvine, California 92618 United StatesSee details»
Cold Genesys Announces Name Change to CG Oncology
Mar 25, 2020 Bing Kung Vice President, Business Development CG Oncology, Inc. (949) 354-4246 [email protected] Contacts Bing Kung Vice President, Business Development CG …See details»
CG Oncology - Craft
Aug 6, 2024 CG Oncology has 1 employees across 2 locations and $204 k in annual revenue in FY 2023. See insights on CG Oncology including office locations, competitors, revenue, …See details»
Executive Leadership - CG Oncology
In addition to leading our business development, corporate strategy, quality, regulatory affairs, and supply chain organization. Ambaw has over 30 years of experience in the biotech industry, and he has a proven track record of …See details»
CG ONCOLOGY INC Career Opportunities
<p>Are you ready to make a difference in the world and become part of our patient-centered team that is focused on Attacking Bladder Cancer for a Better Tomorrow? At CG Oncology, we …See details»
CG Oncology to Present Positive Final Results from Phase 2 CORE …
May 24, 2024 54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 studyIRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG …See details»
CG Oncology Closes $47 Million Series D Financing | CG Oncology
Dec 10, 2020 Learn more at www.cgoncology.com. Contacts. Bing Kung Vice President, Business Development CG Oncology (949) 354-4246 [email protected] or MEDIA …See details»
Careers | Mission | Benefits | Job Opportunities | CG Oncology
REST AND RECHARGE BENEFITS. We offer Unlimited Flexible Time Off benefits for our full-time staff. We believe as long as our team members effectively manage their work …See details»
CG Oncology Announces Nature Medicine Publication of Phase 1b …
Nov 11, 2024 CG Oncology Inc. – Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – …See details»
CG Oncology Initiates Expanded Access Program for
Jun 18, 2024 [email protected]. Investor Relations Laurence Watts New Street IR (619) 916-7620 [email protected]. TagsSee details»
News | Upcoming Conferences | Media Contact | CG Oncology
Dec 6, 2023 [email protected]. Kimberly Ha KKH Advisors (917) 291-5744 [email protected]. Upcoming Conferences Form. I would like to meet with CG …See details»
CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …
2 days ago Website https://cgoncology.com. Full Company Profile. Financial Performance. In 2023, CG Oncology's revenue was $204,000, an increase of 6.81% compared to the previous …See details»
CG Oncology (Nasdaq:CGON) - Simply Wall St
Nov 17, 2024 cgoncology.com: CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for …See details»
Abstracts and Presentations - CG Oncology
CG ONCOLOGY, INC. 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618See details»